Assessing Trifecta Achievement after Percutaneous Cryoablation of Small Renal Masses: Results from a Multi-Institutional Collaboration.
cryoablation
renal cancer
small renal masses
Journal
Medicina (Kaunas, Lithuania)
ISSN: 1648-9144
Titre abrégé: Medicina (Kaunas)
Pays: Switzerland
ID NLM: 9425208
Informations de publication
Date de publication:
03 Aug 2022
03 Aug 2022
Historique:
received:
30
06
2022
revised:
28
07
2022
accepted:
01
08
2022
entrez:
26
8
2022
pubmed:
27
8
2022
medline:
30
8
2022
Statut:
epublish
Résumé
Background and Objectives: To assess efficacy and safety of Percutaneous Cryoablation (PCA) of small renal masses (SRMs) using Trifecta outcomes in a large cohort of patients who were not eligible for surgery. Materials and methods: All PCAs performed in four different centers between September 2009 and September 2019 were retrospectively evaluated. Patients were divided in two different groups depending on masses dimensional criteria: Group-A: diameter ≤ 25 mm and Group-B: diameter > 25 mm. Complications rates were reported and classified according to the Clavien−Dindo system. The estimate glomerular filtration rate (eGFR) was calculated before PCA and during follow-up schedule. Every patient received a Contrast Enhanced Ultrasound (CEUS) evaluation on the first postoperative day. Radiological follow-up was taken at 3, 6, and 12 months for the first year, then yearly. Radiological recurrence was defined as a contrast enhancement persistence and was reported in the study. Finally, Trifecta outcome, which included complications, RFS, and preservation of eGFR class, was calculated for every procedure at a median follow-up of 32 months. Results: The median age of the patients was 74 years. Group-A included 200 procedures while Group-B included 140. Seventy-eight patients were eligible for Trifecta evaluation. Trifecta was achieved in 69.6% of procedures in Group-A, 40.6% in Group-B (p = 0.02). We observed an increased rate of complication in Group-B (13.0% vs. 28.6; p < 0.001). However, 97.5% were <II Clavien−Dindo grade. No differences were found between the two groups regarding eGFR before and after treatment. Further, 24-months RFS rates were respectively 98.0% for Group-A and 92.1% in Group-B, while at 36 months were respectively 94.5% and 87.5% (p = 0.08). Conclusions: PCA seems to be a safe and effective treatment for SRM but in the need of more strict dimensional criteria to achieve a higher possible success rate.
Identifiants
pubmed: 36013508
pii: medicina58081041
doi: 10.3390/medicina58081041
pmc: PMC9412454
pii:
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Références
Eur Urol. 2009 Nov;56(5):786-93
pubmed: 19665284
J Urol. 2013 Jan;189(1):36-42
pubmed: 23164381
Clin Genitourin Cancer. 2022 Jul 16;:
pubmed: 35965197
Eur Urol Oncol. 2021 Apr;4(2):256-263
pubmed: 33384274
Minerva Urol Nefrol. 2020 Dec;72(6):647-649
pubmed: 32432437
Int J Urol. 2015 Nov;22(11):1000-5
pubmed: 26251228
BJU Int. 2021 Oct;128(4):440-450
pubmed: 33991045
Minerva Urol Nephrol. 2021 Aug;73(4):518-524
pubmed: 33769011
J Endourol. 2013 Dec;27(12):1468-70
pubmed: 24074156
Eur Urol Focus. 2021 Nov;7(6):1254-1259
pubmed: 32912840
J Urol. 2017 Sep;198(3):520-529
pubmed: 28479239
Eur Urol. 2015 May;67(5):913-24
pubmed: 25616710
Oncotarget. 2017 Apr 18;8(16):27635-27644
pubmed: 28199973
Minerva Urol Nephrol. 2022 Apr;74(2):194-202
pubmed: 34308610
Eur Urol. 2016 Jan;69(1):116-28
pubmed: 25819723
AJR Am J Roentgenol. 2020 Jul;215(1):242-247
pubmed: 32286877
J Endourol. 2020 Feb;34(2):233-239
pubmed: 31724433
J Endourol. 2012 Nov;26(11):1413-9
pubmed: 22642574
Eur Urol Oncol. 2019 Mar;2(2):207-213
pubmed: 31017098
Curr Urol Rep. 2014 Apr;15(4):396
pubmed: 24623576
J Vasc Interv Radiol. 2012 Jan;23(1):48-54
pubmed: 22037491
Cardiovasc Intervent Radiol. 2021 Jun;44(6):892-900
pubmed: 33388867
World J Urol. 2018 Sep;36(9):1341-1353
pubmed: 29610964
J Ultrasound Med. 2017 Feb;36(2):301-310
pubmed: 27914172
Minerva Urol Nephrol. 2022 Jun;74(3):321-328
pubmed: 33781019
World J Urol. 2014 Feb;32(1):257-63
pubmed: 24013181
Scand J Urol. 2020 Apr;54(2):122-127
pubmed: 32153242
J Med Imaging Radiat Oncol. 2021 Jun;65(3):272-278
pubmed: 33547767
Eur Urol. 2020 Jan;77(1):95-100
pubmed: 30898407
Minerva Urol Nefrol. 2020 Feb;72(1):109-113
pubmed: 31833726
BJU Int. 2012 Aug;110(4):510-6
pubmed: 22304329
Eur Urol Focus. 2018 Mar;4(2):280-287
pubmed: 28753765
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Radiographics. 2010 Jul-Aug;30(4):887-900
pubmed: 20631358
J Natl Cancer Inst. 2006 Sep 20;98(18):1331-4
pubmed: 16985252
Urology. 2014 May;83(5):1081-7
pubmed: 24560975
Urology. 2015 Apr;85(4):850-5
pubmed: 25704992
J Endourol. 2008 May;22(5):963-7
pubmed: 18643721
J Cancer. 2019 Jan 29;10(5):1226-1236
pubmed: 30854132
BJU Int. 2015 Sep;116(3):407-14
pubmed: 25220543
Urol Oncol. 2020 Dec;38(12):938.e1-938.e7
pubmed: 33036899